ReviewCureus2025
Vitrectomy Alone Versus Anti-vascular Endothelial Growth Factor (Anti-VEGF) Therapy Prior to Vitrectomy for Diabetic Vitreous Hemorrhage: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Etiological Spectrum and Visual Outcomes of Spontaneous Vitreous Hemorrhage.Beyoglu eye journal · 2026Article
- Clinical efficacy of Conbercept combined with pars plana vitrectomy for proliferative diabetic retinopathy.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proliferative diabetic retinopathy (PDR) affects approximately 1.5% of adults with diabetes and is a leading cause of blindness due to complications such as vitreous hemorrhage. Pan-retinal photocoagulation (PRP) has been the mainstay of treatment for many years. Still, the advent of anti-vascular endothelial growth factor (anti-VEGF) agents, including ranibizumab, bevacizumab, and aflibercept, presents successful therapeutic options. This study aims to conduct a systematic review and meta-analysis to compare the efficacy of anti-VEGF therapy combined with vitrectomy versus vitrectomy alone in patients with vitreous hemorrhage due to diabetic retinopathy. Many electronic sources, such as PubMed and Google Scholar, were searched for pertinent literature. PICOS (population, intervention, comparison, outcomes, and study) criteria were applied to select the studies systematically. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) framework was employed to synthesize and report data. The analysis included six studies with a total of 468 patients. Results indicated a significant improvement in best-corrected visual acuity (BCVA) at three months in the anti-VEGF group compared to vitrectomy alone (MD = -0.19; p = 0.02), while no significant differences were found at one month (MD = 0.08; p = 0.50) and six months (MD = 0.03; p = 0.40). Additionally, no significant differences in recurrent vitreous hemorrhage rates were observed between groups. In conclusion, anti-VEGF drugs combined with vitrectomy showed significant improvements in BCVA at three months as compared to vitrectomy alone, indicating their potential effectiveness for diabetic vitreous hemorrhages. However, the scarcity of available research emphasizes the necessity of carrying out extensive clinical trials to validate the safety and efficacy of anti-VEGF treatment as compared to alternative treatment options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.